
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.
Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.
4.6
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.
Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.
127 Listeners
6 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
10 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
131 Listeners
4 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
317 Listeners
2 Listeners
95 Listeners
13 Listeners
275 Listeners
2 Listeners
688 Listeners
3,318 Listeners
91 Listeners
1,084 Listeners
175 Listeners
285 Listeners
513 Listeners
48 Listeners
8,648 Listeners